There is a good news for the abdominally obese patients with cardiometabolic risk factors living in
First time the weight loss diet pill acomplia has been launched in the Middle East.The diet pill is already available in Europe ,
In a servey by Sanofi it is pointed out that 37 percent of the UAE population has been obese which is a highest obesity rates in the
Dr. Wael Al Mahmeed, Vice President of the Emirates Cardiac Society said,"Among people who are overweight or obese, it is those with excess fat around their abdomen who are at the greatest risk of developing an abnormal lipid profile, type 2 diabetes and ultimately heart disease."
He also added,"Rimonabant is an important advance in the treatment of cardio-metabolic risk factors which contribute to the global risk for diabetes and cardiovascular disease."
No comments:
Post a Comment